<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37120490</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Serum salusin-&#x3b2; levels in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>2097</StartPage><EndPage>2103</EndPage><MedlinePgn>2097-2103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06610-y</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Endothelial dysfunction (ED) has an important role in the pathogenesis of systemic lupus erythematosus (SLE). Studies on other inflammatory diseases show that salusin-&#x3b2; with various mechanisms may play a role in the promotion of ED and inflammation. The aim of this study was to measure serum salusin-&#x3b2; levels in SLE patients and evaluate it as a potential biomarker in assessing SLE activity and predicting organ involvement.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a cross-sectional study, 60 patients diagnosed with SLE and 30 age- and sex-matched healthy controls were enrolled. Disease activity of SLE patients was assessed by the systemic lupus erythematosus disease activity index 2000 (SLEDAI-2&#xa0;K). Serum levels of salusin-&#xdf; were measured using a human salusin-&#xdf; enzyme-linked immunosorbent assay kit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum salusin-&#x3b2; levels in SLE and control groups were 474.2&#x2009;&#xb1;&#x2009;117.1&#xa0;pg/ml and 157.7&#x2009;&#xb1;&#x2009;88.7&#xa0;pg/ml, respectively. The difference was significant (P&#x2009;=&#x2009;0.001). There was no significant correlation between serum salusin-&#x3b2; levels with age (r&#x2009;=&#x2009;&#x2009;-&#x2009;0.06, P&#x2009;=&#x2009;0.632) and SLEDAI (r&#x2009;=&#x2009;&#x2009;-&#x2009;0.185, P&#x2009;=&#x2009;0.158). In patients with nephritis and thrombosis, serum salusin-&#x3b2; was significantly higher. In addition, in patients with serositis, serum salusin-&#x3b2; was significantly lower. Multiple linear regression analysis showed that serum salusin-&#x3b2; levels retained a significant association with nephritis and thrombosis after model adjustment for serositis, nephritis, and thrombosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings showed that salusin-&#x3b2; might have a possible role in the pathogenesis of SLE. Salusin-&#x3b2; may be a potential biomarker for nephritis and thrombosis in SLE. Key Points &#x2022; Serum salusin-&#x3b2; levels were significantly higher in SLE patients than the control group. &#x2022; There was no significant correlation between serum salusin-&#x3b2; levels with age and SLEDAI. &#x2022; Serum salusin-&#x3b2; levels retained a significant association with nephritis and thrombosis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hajialilo</LastName><ForeName>Mehrzad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorjani</LastName><ForeName>Razieh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahimi</LastName><ForeName>Mehran</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbanihaghjo</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malek Mahdavi</LastName><ForeName>Aida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rahat Breathe and Sleep Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghojazadeh</LastName><ForeName>Morteza</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center for Evidence-Based Medicine, A Joanna Briggs Institute Affiliated Group, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khabbazi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9482-6967</Identifier><AffiliationInfo><Affiliation>Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St, P.O Box 5166614756, Tabriz, Iran. dr_khabbazi@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>63897</GrantID><Agency>Connective Tissue Diseases Research Center of Tabriz University of Medical Sciences, Tabriz, Iran</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012700" MajorTopicYN="Y">Serositis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009393" MajorTopicYN="Y">Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease activity</Keyword><Keyword MajorTopicYN="N">Organ involvement</Keyword><Keyword MajorTopicYN="N">Salusin-&#x3b2;</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>23</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37120490</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06610-y</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06610-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pisetsky DS (2020) Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun 110:102356</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102356</ArticleId><ArticleId IdType="pubmed">31810857</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Tektonidou MG (2020) Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford) 59(Suppl5):v29&#x2013;v38</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa382</ArticleId><ArticleId IdType="pubmed">33280012</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Qu B, Shen N (2022) Expanding roles of noncoding RNAs in the pathogenesis of systemic lupus erythematosus. Curr Rheumatol Rep 24(3):64&#x2013;75</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-022-01058-6</ArticleId><ArticleId IdType="pubmed">35239107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Nagafuchi Y, Fujio K (2021) Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules 11(7):928</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070928</ArticleId><ArticleId IdType="pubmed">34206696</ArticleId><ArticleId IdType="pmc">8301935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH (2017) Endothelial dysfunction in systemic lupus erythematosus &#x2013; a case-control study and an updated meta-analysis and meta-regression. Sci Rep 7(1):7320</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07574-1</ArticleId><ArticleId IdType="pubmed">28779080</ArticleId><ArticleId IdType="pmc">5544707</ArticleId></ArticleIdList></Reference><Reference><Citation>Taraborelli M, Sciatti E, Bonadei I, Terlizzi V, Fredi M, Zani R, Cancarini G, Tincani A, Franceschini F, Vizzardi E, Cavazzana I (2018) Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events. Arthritis Care Res (Hoboken) 70(9):1277&#x2013;1283</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23495</ArticleId><ArticleId IdType="pubmed">29245186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, Leung J, Shalish C, Bressman SB, de Leon D, Brin MF, Fahn S, Corey DP, Breakefield XO (1999) The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics 62(3):377&#x2013;384</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1999.6039</ArticleId><ArticleId IdType="pubmed">10644435</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y (2003) Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med 9(9):1166&#x2013;1172</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm913</ArticleId><ArticleId IdType="pubmed">12910263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Watanabe R, Itoh F, Shichiri M, Watanabe T (2013) Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases. Int J Hypertens 2013:965140</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/965140</ArticleId><ArticleId IdType="pubmed">24251033</ArticleId><ArticleId IdType="pmc">3819761</ArticleId></ArticleIdList></Reference><Reference><Citation>Erden I, Demir B, U&#xe7;ak H, Cicek D, Dertlio&#x11f;lu SB, Aydin S (2014) Serum salusin-&#x3b1; and salusin-&#x3b2; levels in patients with Behcet&#x2019;s disease. Eur J Dermatol 24(5):577&#x2013;582</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/ejd.2014.2397</ArticleId><ArticleId IdType="pubmed">25115151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozgen M, Koca SS, Dagli N, Balin M, Ustundag B, Isik A (2011) Serum salusin-alpha level in rheumatoid arthritis. Regul Pept 167(1):125&#x2013;128</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.regpep.2010.12.003</ArticleId><ArticleId IdType="pubmed">21185876</ArticleId></ArticleIdList></Reference><Reference><Citation>Koca SS, &#xd6;zgen M, I&#x15f;&#x131;k B, Da&#x11f;l&#x131; MN, &#xdc;st&#xfc;nda&#x11f; B, I&#x15f;&#x131;k A (2014) Serum salusin-&#x3b1; levels in systemic lupus erythematosus and systemic sclerosis. Eur J Rheumatol 1(1):14&#x2013;17</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2014.004</ArticleId><ArticleId IdType="pubmed">27708865</ArticleId><ArticleId IdType="pmc">5042256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowaczyk J, Blicharz L, Zawistowski M, Sikora M, Zaremba M, Czuwara J, Rudnicka L (2023) The clinical significance of salusins in systemic sclerosis-a cross-sectional study. Diagnostics (Basel) 13(5):848</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13050848</ArticleId><ArticleId IdType="pubmed">36899991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak S, Atabay T, Akyildiz M, Gokduman A, Vural H (2022) Serum salusin-&#x3b1; and salusin-&#x3b2; levels in patients with psoriatic arthritis. Reumatologia 60(5):306&#x2013;310</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2022.120753</ArticleId><ArticleId IdType="pubmed">36381209</ArticleId><ArticleId IdType="pmc">9661408</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstr&#xf8;m K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirj&#xe1;k L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kum&#xe1;novics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, R&#xfa;a-Figueroa Fern&#xe1;ndez &#xcd;, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, D&#xf6;rner T, Johnson SR (2019) 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71(9):1400&#x2013;1412</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId><ArticleId IdType="pmc">6827566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Fujimoto K, Koyama T, Shichiri M (2010) Release of salusin-beta from human monocytes/macrophages. Regul Pept 162(1&#x2013;3):68&#x2013;72</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.regpep.2010.02.010</ArticleId><ArticleId IdType="pubmed">20176058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Sato T, Susumu T, Koyama T, Shichiri M (2009) Presence of immunoreactive salusin-beta in human plasma and urine. Regul Pept 158(1&#x2013;3):63&#x2013;67</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.regpep.2009.07.017</ArticleId><ArticleId IdType="pubmed">19660505</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumiyama H, Tanaka H, Egi K, Sunamori M, Hirata Y, Shichiri M (2005) Synthetic salusins as cardiac depressors in rat. Hypertension 45(3):419&#x2013;425</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000156496.15668.62</ArticleId><ArticleId IdType="pubmed">15699450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun HJ, Liu TY, Zhang F, Xiong XQ, Wang JJ, Chen Q, Li YH, Kang YM, Zhou YB, Han Y, Gao XY, Zhu GQ (2015) Salusin- &#x3b2; contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. Biochim Biophys Acta 1852(9):1709&#x2013;1718</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.05.008</ArticleId><ArticleId IdType="pubmed">26001930</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto K, Hayashi A, Kamata Y, Ogawa A, Watanabe T, Ichikawa R, Iso Y, Koba S, Kobayashi Y, Koyama T, Shichiri M (2013) Circulating levels of human salusin-&#x3b2;, a potent hemodynamic and atherogenesis regulator. PLoS One 8(10):e76714</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076714</ArticleId><ArticleId IdType="pubmed">24098553</ArticleId><ArticleId IdType="pmc">3789687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang S, Zhang J, Zhang M, Zhang H, Gong G, Luo M, Wang T, Mao X (2020) Salusin- &#x3b2; is superior to salusin-&#x3b1; as a marker for evaluating coronary atherosclerosis. J Int Med Res 48(2):300060520903868</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060520903868</ArticleId><ArticleId IdType="pubmed">32054363</ArticleId></ArticleIdList></Reference><Reference><Citation>Koya T, Miyazaki T, Watanabe T, Shichiri M, Atsumi T, Kim-Kaneyama JR, Miyazaki A (2012) Salusin-&#x3b2; accelerates inflammatory responses in vascular endothelial cells via NF-&#x3ba;B signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. Am J Physiol Heart Circ Physiol 303(1):H96-105</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00009.2012</ArticleId><ArticleId IdType="pubmed">22561298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24(2):303&#x2013;308</Citation><ArticleIdList><ArticleId IdType="pubmed">9034987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Jin G (2021) Downregulation of salusin-&#x3b2; protects renal tubular epithelial cells against high glucose-induced inflammation, oxidative stress, apoptosis and lipid accumulation via suppressing miR-155-5p. Bioengineered 12(1):6155&#x2013;6165</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1972900</ArticleId><ArticleId IdType="pubmed">34482798</ArticleId><ArticleId IdType="pmc">8806677</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot PG, de Laat B (2017) Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 31(3):334&#x2013;341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2017.09.008</ArticleId><ArticleId IdType="pubmed">29224675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, Du Q, Wang HP, Tang ZH, Wang YB, Sun HJ (2020) Salusin-&#x3b2; mediates tubular cell apoptosis in acute kidney injury: involvement of the PKC/ROS signaling pathway. Redox Biol 30:101411</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101411</ArticleId><ArticleId IdType="pubmed">31884071</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>